Eric Blair, Chief Business Officer and Singapore Country Executive

April 9 | 4:45pm | Salone dei Cavalieri, Section 2

Nucleos, Singapore


GeneFab is a contract research and manufacturing organization focused on cell and gene therapies. GeneFab was formed in 2023 with a vision to combine industry leading expertise in synthetic biology with advanced cGMP capabilities in order to accelerate the development and commercialization of genetic medicines. GeneFab capabilities spans early-stage product design, technical development and cGMP compliant production including CAR-T/CAR-NK Cells, iPSCs, engineered cell banks, AAV, lentiviral vectors, gamma-retroviral vectors, mRNA, LNP and pDNA. GeneFab’s technology platform includes bioinformatic-guided discovery of cell type promoters, directed evolution of small molecule-regulated gene switches, the engineering of highly sensitive kill switches for enhanced safety and control of cellular therapies, and innovator-centric manufacturing platforms to accelerate novel therapies to patients in need. Across two facilities in Alameda and South San Francisco and facility soon in Singapore, GeneFab employs approximately 100 employees, including experts in cell, gene, and nucleic acid therapy, CMC, analytical development, process development and synthetic biology.

By using this website you agree to accept our Privacy Policy and Terms & Conditions